Previous studies showed that numerous drugs can inhibit Ang II-induced cardiac hypertrophy as well as the associated inflammation and oxidative stress via modulating the NF-κB pathway (Ren et al., 2021; Ma et al., 2023). This evidence concerns the gene NFKB1 and cardiac hypertrophy.